Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

圣路易斯华盛顿大学的 Ziyad Al-Aly 团队，借助退伍军人事务部数据库，历经约四年，跟踪超21.5万名使用 GLP-1 药物的患者，并于 2025 年 1 月 20 日在《Nature Medicine》发表了题为 “Mapping the ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

这项由圣路易斯退伍军人事务部医疗保健系统（Veterans Affairs St. Louis Health Care System）的研究人员主导的研究发现，这些GLP-1类药物可以降低多种健康问题的风险，包括药物滥用障碍、自杀倾向、精神分裂症和其他精神病性障碍等。研究还发现，这些药物能降低神经认知障碍（如阿尔茨海默病和老年痴呆）、感染、肝癌，甚至是威胁生命的血栓性疾病（如肺部血栓）的风险。

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Recent study held under Dr. Ziyada Al-Aly found that GLP-1 medications can reduce the risk of disease like heart disease and ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...